speb/financial-data huggingface dataset:
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 6742322000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 586276000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 499125000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Depreciation: 1129900000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 1129900000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 755300000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 144900000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 755300000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 144900000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 194751244.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 196081081.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Diluted EPS: 4.02
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.74
SHILPAMED.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 782900000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 145100000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 1674000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 1674000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — EBIT: 2353200000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — EBIT: 440600000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — EBITDA: 3483100000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — EBITDA: 585500000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: 10200000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — End Cash Position: 285700000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: 626500000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 494222000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 494222000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: -1114100000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -42600000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: -2714000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 278908000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Goodwill: 462308000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 462308000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 5646478000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 5646478000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 4434493000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 4434493000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 16749596000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 16749596000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Gross Profit: 8760400000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 2263300000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Hedging Assets Current: 1178000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 1178000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Impairment Of Capital Assets: -25000000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Impairment Of Capital Assets: -25000000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Interest Expense: 1129900000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 287900000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 1129900000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 287900000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Interest Income: 80315000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 80315000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -767300000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 80500000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Inventory: 3479277000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 3479277000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 29494345000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 29494345000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -1991300000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 276794000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 407914000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Investments In Other Ventures Under Equity Method: 53192000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Investments In Other Ventures Under Equity Method: 53192000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Investmentsin Joint Venturesat Cost: 17276000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Joint Venturesat Cost: 17276000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 4891000000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 618655000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 618655000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 12481000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 12481000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 2319569000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 2319569000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 2332050000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 2332050000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 70468000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 70468000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 255413000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 255413000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 9617827000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 9617827000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Minority Interest: -85382000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: -85348000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Minority Interests: 0.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Minority Interests: 0.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: 89900000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 4891000000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Net Debt: 5603943000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 5603943000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -43100000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Net Income: 783000000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Net Income: 145100000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 782900000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 145100000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 783000000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 145100000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 783000000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 145100000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 783000000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 145100000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 1223300000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 783000000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 145100000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Net Interest Income: -1129900000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -287900000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 9392000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: -3491700000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -2953000000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -1129900000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -287900000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Net Other Financing Charges: 2000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Net Other Investing Changes: 275100000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Net PPE: 17054445000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 17054445000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -2436800000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: -538700000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 18075886000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 18075886000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Revenue: 139953000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 139953000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 129656000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 129656000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 255413000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 255413000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 61586000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 61586000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 3788900000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 891300000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Normalized Income: 978709000.25
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 435479829.73
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 1322700000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Operating Income: 2438400000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Operating Income: 647200000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Operating Revenue: 12864300000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 3308200000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 97790908.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 97790908.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Other Cash Adjustment Outside Changein Cash: 2000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: -10720000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: -10720000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 432584000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 432584000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 23624602000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 23624602000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 5184170000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 5184170000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Other Inventories: 269517000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 269517000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: 577400000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 316710000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 10927000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: 140278000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 140278000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 233300000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 76300000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 2639600000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 761900000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Other Payable: 881502000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 881502000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Other Properties: 12124380000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 12124380000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 317568000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 317568000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 325926000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 325926000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Other Special Charges: 320600000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Other Special Charges: 320600000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 100000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Payables: 953815000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Payables: 1952284000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 292956000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 292956000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 409333000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 409333000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Pretax Income: 1223300000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 152700000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 63500000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -2436800000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 2102601000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 2102601000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 4103900000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 1044900000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 1129900000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 144900000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 14723000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 14723000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Research And Development: 483734000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 25554000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 25554000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 10970885000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 10970885000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Sale Of Business: 89900000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 275051000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 117339000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 396247000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Share Issued: 97790908.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 97790908.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Special Income Charges: -305800000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: -305800000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 23630719000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 23722364000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 18075886000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 17984241000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: -110090999.75
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -15420170.27
SHILPAMED.NS income_statement (annual, 2025-03-31) — Tax Provision: 440400000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 7700000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.36
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.05
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 47320000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 966496000.00
SHILPAMED.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -470200000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Total Assets: 33107079000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 33107079000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 26041933000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 26041933000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Total Debt: 5877468000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 5877468000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 23637016000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 23637016000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Total Expenses: 10425900000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 2661000000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 9470063000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 9561742000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 23250354000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 23250354000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 2727741000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 2819420000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 167683000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 115293000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 115293000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Total Unusual Items: -305800000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: -305800000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: -305800000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -305800000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Work In Process: 612937000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 612937000.00
SHILPAMED.NS balance_sheet (annual, 2025-03-31) — Working Capital: 3114403000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 3114403000.00
SHILPAMED.NS income_statement (annual, 2025-03-31) — Write Off: 10200000.00
SHILPAMED.NS income_statement (quarterly, 2025-03-31) — Write Off: 10200000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 1791359000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 3214574000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 195764509.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 2.40
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 796060000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 289203000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 289203000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 195764509.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 2.40
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 468856000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — EBIT: 683612000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — EBITDA: 972815000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 2418514000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 187812000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 187812000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Minority Interests: 0.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Net Income: 468856000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 468856000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 468856000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 468856000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 468856000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 468856000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -187812000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -187812000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 972815000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 468856000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Operating Income: 627155000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 3214574000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 63787000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 684016000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 495800000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 796060000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 289203000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 26944000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.05
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 2587419000.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
SHILPAMED.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 1860142000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 3699688000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 1650203000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 4268811000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Assets Held For Sale Current: 190560000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 386979000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 195581816.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 1.13
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 19991000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 97791000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 179525000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 535500000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 97791000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 24371985000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 5337291000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 1054971000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 10587777000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 5621000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 4016667000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 4022288000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 7803309000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 307087000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 298228000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 298228000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 195581816.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 1.13
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 440667000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — EBIT: 800977000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — EBITDA: 1099205000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Goodwill: 462308000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 6087688000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 17255699000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 2644717000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 156680000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 156680000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 4448686000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 30284542000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 386979000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 14370000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 1895890000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 1910260000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 275777000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Minority Interest: 13221000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Minority Interests: 0.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Net Debt: 5733032000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Net Income: 440667000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 440667000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 440667000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 440667000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 440667000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 440667000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -156680000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -156680000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 17255699000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 18284297000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 277004000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 1099205000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 440667000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Operating Income: 784575000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 3699688000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 195581816.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 1144220000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 310581000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 24274194000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 5625380000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 355937000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 576532000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 17544000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 731393000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 11918408000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 355975000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Payables: 1754378000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 644297000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 1054971000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 298228000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 195581816.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 24371985000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 18284297000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 203630000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.32
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 0.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 34951084000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 26267875000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 5932548000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 24385206000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 2915113000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 10565878000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 24363307000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 2762569000.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 104175000.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: 0.00
SHILPAMED.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 0.00
SHILPAMED.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 2784468000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 1924674000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 4097267000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 188907627.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 2.36
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 1333232000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 303644000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 303644000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 188907627.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 2.36
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 445822000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — EBIT: 715351000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — EBITDA: 1018995000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 2764035000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 106818000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 106818000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Minority Interests: 0.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Net Income: 445822000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 445822000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 445822000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 445822000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 445822000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 445822000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -106818000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -106818000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 1147607000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 540045417.73
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Operating Income: 839361000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 4097267000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 8143000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 786482000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 608533000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 1333232000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 303644000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -128612000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -34388582.27
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 162711000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.27
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 3257906000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -128612000.00
SHILPAMED.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -128612000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — +Operating Expense: 7025400000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 1889500000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — +Total Revenue: 15388700000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 4369900000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 1424700000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 1424700000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 5188500000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 5188500000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 652400000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 652400000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 195602894.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 195626134.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Basic EPS: 12.44
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 5.51
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 285700000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -3706300000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 18900000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 18900000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 195600000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 195600000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 412600000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 412600000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 916900000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 916900000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -97800000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -369900000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: 48100000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 288600000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Change In Payable: 346700000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -665200000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -351700000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 298800000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Common Stock: 195600000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 195600000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 25912000000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 25912000000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 0.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 4312000000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 4312000000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 4604100000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 1419900000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Current Assets: 11097700000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 11097700000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 5700000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 5700000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Current Debt: 4741600000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 4741600000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 4747300000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 4747300000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 8480600000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 8480600000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 411100000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 411100000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Depreciation: 1197200000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 1197200000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 587900000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 136600000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 587900000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 136600000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 195602894.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 195626134.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Diluted EPS: 12.44
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 5.51
SHILPAMED.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 2433300000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 1077900000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — EBIT: 4150300000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — EBIT: 1510700000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — EBITDA: 5347500000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — EBITDA: 1647300000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: -132700000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — End Cash Position: 451800000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: 136200000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: -284500000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -306300000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Goodwill: 468600000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 468600000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 6950700000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 6950700000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 17821000000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 17821000000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Gross Profit: 10784600000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 2950000000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Impairment Of Capital Assets: -56300000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Impairment Of Capital Assets: -56300000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Interest Expense: 1197200000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 306200000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 1197200000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 306200000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -476000000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 6500000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Inventory: 3667900000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 3667900000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 32491700000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 32491700000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -3259200000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 652400000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 652400000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 0.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 13200000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 13200000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 1838100000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 1838100000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 1851300000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 1851300000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 332000000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 332000000.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Minority Interest: 0.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: 0.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Minority Interests: 0.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Minority Interests: 0.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Net Business Purchase And Sale: 308100000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 0.00
SHILPAMED.NS balance_sheet (annual, 2026-03-31) — Net Debt: 6167100000.00
SHILPAMED.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 6167100000.00
SHILPAMED.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -284700000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Net Income: 2433300000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Net Income: 1077900000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 2433300000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 1077900000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 2433300000.00
SHILPAMED.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 1077900000.00
SHILPAMED.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 2433300000.00